Loading... (0%)
About liver disease
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more
The NASH Education Program: An initiative by GENFIT
LEARN MORE
Elafibranor phase 3 study in NASH with fibrosis is currently recruiting patients all around the world.
LEARN MORE

Press releases
  • GENFIT: Convening Notice to the Ordinary and Extraordinary Shareholders Meeting on June 16, 2017
    05/12/2017
  • GENFIT: First Patient enrolled in a Phase 2 Trial recruiting Adults with Primary Biliary Cholangitis (PBC), a Rare Liver Disease
    05/05/2017
  • GENFIT: Publication of the 2016 Registration Document
    04/28/2017
  • GENFIT: Q1 2017 Financial Information
    04/24/2017
  • GENFIT: The NASH Education Program™ – Inaugural Press Conference, Paris – March 9, 2017
    02/14/2017
Events